Constellium SE (CSTM) Stock Price & Analysis
Constellium SE (CSTM) closed at USD 24.43 on Wednesday, October 28, 2026, down 0.53% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 24.56; the Oct 28, 2026 session ranged USD 23.38–25 on volume of 4,261,071 shares. Market capitalization is $3.31B, with a 52-week range of USD 14.62–36.99 (NYQ). Source: Nexqual, retrieved October 29, 2026 at 06:47 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CSTM.md
Key facts (CSTM)
- Last four reported quarters (through Jun 30, 2026): revenue $9.58B, net income $545M (5.7% margin), free cash flow $218M (SEC filings).
- Valuation: P/E 6.1x (avg 18.8x at the last 3 fiscal year-ends), net debt $1.76B.
- Insider open-market sales, last ~7 months: 11 Form 4 filings, $6.4M; 11 not under a Rule 10b5-1 plan ($6.4M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $166K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.33 on a 1–5 scale) (6 analysts), mean target USD 33.45 (range 27.85–36.9).
- Total return with dividends: 1Y +50.1% vs S&P 500 +13.6%; 5Y +32.7% vs S&P 500 +79.8%.
- Next earnings: 2026-10-28, EPS estimate USD 0.57, revenue estimate $2.17B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CSTM)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $8.53B | $7.83B | $7.33B | $8.45B | $9.58B |
| Net income | $308M | $152M | $56.0M | $273M | $545M |
| EPS (diluted) | $2.10 | $1.03 | $0.38 | $1.92 | — |
| Free cash flow | $76.0M | $66.0M | -$112M | $159M | $218M |
| Net margin | 3.6% | 1.9% | 0.8% | 3.2% | 5.7% |
| Revenue growth | — | -8.3% | -6.3% | +15.2% | — |
| Cash + short-term investments | $176M | $223M | $141M | $120M | — |
| Total debt | — | $1.93B | $1.92B | $1.94B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CSTM)
P/E 6.1x · P/S 0.3x · EV/Sales 0.5x · P/FCF 15.2x · P/B 2.7x · FCF yield 6.58% · Earnings yield 16.46% · Buyback yield (TTM) 3.41% · Net debt $1.76B · EV $5.07B
P/E at fiscal year-ends: Dec 2025 9.8x, Dec 2024 27.1x, Dec 2023 19.5x.
Insider sales (SEC Form 4, open-market, last ~7 months) (CSTM)
0 of 11 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Ormerod John | Director | 8,000 | $280K | 24.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-28 | Becker Marcus | SVP CPO | 10,391 | $363K | 38.2% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-14 | Jarrett Martin | SVP Chief Innovation Officer | 4,716 | $158K | 23.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-12 | Piquier Ludovic | SVP Manuf Excellence & CTO | 1,000 | $34K | 0.4% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-11 | Brun Nicolas | SVP PA, Comm & Sust | 26,661 | $902K | 20.3% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-08 | Corre Stephane | President, AS&I | 5,000 | $168K | 7.4% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-05 | Brandjes Michiel | Director | 10,400 | $325K | 20% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-05 | Guo Jack Q. | EVP & CFO | 25,201 | $822K | 12% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Hoffmann Philippe | President, A&T | 50,000 | $1.6M | 25.8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Jurkovic Philip Ryan | SVP & CHRO | 48,784 | $1.6M | 22.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Corre Stephane | President, AS&I | 5,000 | $160K | 6.9% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Insider purchases (SEC Form 4, open-market, last ~7 months) (CSTM)
3 purchases, $166K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-03 | Deslarzes Jean-Christophe | Director | 1,490 | $41K | 27.24 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-14 | Soultz Bradley Lee | Director | 2,500 | $85K | 33.84 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Deslarzes Jean-Christophe | Director | 1,325 | $41K | 31.13 | Too little history (no open-market trades in 2023–2025) |
Analysts (CSTM)
Consensus Buy (mean 2.33 on a 1–5 scale), 6 analysts; mean target USD 33.45 (low 27.85, high 36.9).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Barclays | Initiated | Equal-Weight | $28 |
| 2026-10-08 | UBS | Target lowered | Buy | $34 → $32 |
| 2026-10-08 | Deutsche Bank | Target lowered | Buy | $39 → $36 |
| 2026-09-18 | Wells Fargo | Target lowered | Overweight | $39 → $38 |
| 2026-07-30 | Wells Fargo | Target raised | Overweight | $37 → $39 |
| 2026-07-09 | Wells Fargo | Target lowered | Overweight | $39 → $37 |
| 2026-07-08 | UBS | Target lowered | Buy | $38 → $35 |
Total return (dividends reinvested) (CSTM)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +50.1% | +32.7% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +50.4% | +5.8% |
| Volatility (annualized) | 44.4% | 41.7% |
| Max drawdown | -35.8% (Jun 2026→Oct 2026) | -64.1% (Apr 2024→Apr 2025) |
CSTM earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Jul 29, 2026 | Quarter ended Jun 30, 2026 | $1.35 | $0.84 | Beat +60.7% | -1.8% |
| Apr 29, 2026 | Quarter ended Mar 31, 2026 | $1.02 | $0.51 | Beat +100.0% | +0.6% |
| Feb 18, 2026 | Quarter ended Dec 31, 2025 | $0.68 | $0.32 | Beat +112.5% | +10.3% |
| Oct 29, 2025 | — | — | — | — | -4.3% |
| Jul 29, 2025 | — | — | — | — | +6.0% |
| Apr 30, 2025 | — | — | — | — | +12.4% |
| Feb 20, 2025 | — | — | — | — | +15.0% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
CSTM recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 28, 2026 | 10-Q | Quarterly report · period ended Sep 30, 2026 |
| Oct 28, 2026 | 8-K | Quarterly results |
| Aug 6, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 1.6% of shares, passive 5%+ holder (amended) |
| Jul 29, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Jul 29, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
CSTM revenue by business segment (quarter ended Sep 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| P&ARP | $1.63B | 61.6% | +24.3% |
| A&T | $664.0M | 25.2% | +38.0% |
| AS&I | $402.0M | 15.2% | -1.7% |
| H&C | $2.0M | 0.1% | +100.0% |
| Total revenue | $2.64B | 100% | — |
CSTM revenue by product line (quarter ended Sep 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Packaging rolled products | $1.19B | 45.0% | +20.6% |
| Automotive rolled products | $407.0M | 15.4% | +37.0% |
| Aerospace rolled products | $329.0M | 12.5% | +24.6% |
| Transportation, industry, defense and other rolled products | $298.0M | 11.3% | +49.7% |
| Automotive extruded products | $241.0M | 9.1% | -6.9% |
| Other extruded products | $149.0M | 5.6% | +6.4% |
| Specialty and other thin-rolled products | $28.0M | 1.1% | +21.7% |
| Total revenue | $2.64B | 100% | — |
CSTM revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $3.31B | 39.2% | +33.8% |
| Other Geographical Areas | $1.62B | 19.1% | +8.6% |
| Germany | $1.54B | 18.2% | +1.2% |
| France | $722.0M | 8.5% | +3.9% |
| Spain | $376.0M | 4.5% | +2.5% |
| United Kingdom | $367.0M | 4.3% | +15.8% |
| Poland | $317.0M | 3.8% | +18.7% |
| Czechia | $205.0M | 2.4% | -1.9% |
| Total revenue | $8.45B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CSTM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Dec 2026) | $0.57 | $0.43 | +32.3% | $2.17B | 1 |
| Next quarter (ends Mar 2027) | $0.63 | $0.63 | +0.5% | $2.19B | 1 |
| Current fiscal year (ends Dec 2026) | $3.53 | $3.06 | +15.3% | $8.87B | 1 |
| Next fiscal year (ends Dec 2027) | $2.62 | $2.55 | +2.7% | $8.99B | 1 |
CSTM options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 39.3% | ±8.0% |
| Dec 18, 2026 | 51 | 26.3% | ±10.0% |
| Jan 15, 2027 | 79 | 44.7% | ±16.5% |
| Feb 19, 2027 | 114 | 47.1% | ±20.8% |
| May 21, 2027 | 205 | 55.3% | ±32.5% |
30-day implied volatility 43.8% vs 31.9% realized over the last 30 trading days. Put/call ratio (volume) 0.61. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 06:47 UTC)
| Price | USD 24.43 |
|---|---|
| Change | ▼ 0.53% (down) |
| Previous Close | USD 24.56 |
| Open | USD 24.6 |
| Day Range | USD 23.38 – 25 |
| 52-Week Range | USD 14.62 – 36.99 |
| Volume | 4,261,071 shares |
| Market Cap | $3.31B |
| Exchange | NYQ |
Technical Analysis (CSTM)
Nexqual's technical model rates CSTM "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 06:47 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.04 (neutral) |
| vs SMA50 | Below (USD 25.68) |
| MACD | -0.44 (negative) |
Analyst Ratings (CSTM)
Wall Street analysts rate CSTM "Buy" based on 6 analysts, with a mean price target of USD 33.45 (range USD 27.85–36.9), per Nexqual as of October 29, 2026 at 06:47 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 33.45 |
| High Target | USD 36.9 |
| Low Target | USD 27.85 |
| Buy / Hold / Sell | 4 / 2 / 0 |
Earnings (CSTM)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 0.57 |
| Revenue Estimate | $2.17B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-09-30 | USD 0.72 vs est 0.75 ▼ miss |
| 2026-06-30 | USD 1.35 vs est 0.84 ▲ beat |
| 2026-03-31 | USD 1.02 vs est 0.51 ▲ beat |
| 2025-12-31 | USD 0.68 vs est 0.32 ▲ beat |
Source: Nexqual, October 29, 2026 at 06:47 UTC.
Financials & Fundamentals (CSTM)
| Total Revenue | $9.58B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +30.70% |
| Gross Margin | +16.55% |
| Operating Margin | +8.92% |
| Profit Margin | +5.69% |
| ROE | +53.09% |
| Debt / Equity | 1.53 |
| Current Ratio | 1.43 |
| Total Cash | $163.00M |
| Total Debt | $1.92B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $218.00M (2.3% of revenue) |
Source: Nexqual, October 29, 2026 at 06:47 UTC.
Financial Health Score (CSTM)
Nexqual rates Constellium SE's overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 06:47 UTC.
| Growth | Mixed — Revenue +1.6% YoY (annual), slow |
|---|---|
| Profitability | Mixed — Gross margin 17%, operating 9% (last 12 months) |
| Balance Sheet | Weak — $163M cash and investments vs $1.92B debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $218M (last 4 quarters to Jun 2026, SEC), slim 2.3% margin |
| Efficiency | Strong — ROE 44%, ROA 9.0% (last 4 quarters, SEC) |
Ownership (CSTM)
| Insider Ownership | +3.02% |
|---|---|
| Institutional Ownership | +92.36% |
| Shares Outstanding | 135.53M |
| Float | 123.43M |
| Short % of Float | +4.38% |
Source: Nexqual, October 29, 2026 at 06:47 UTC.
Leadership (CSTM)
Constellium SE is led by Ingrid Joerg, CEO & Director, per Nexqual as of October 29, 2026 at 06:47 UTC.
| CEO & Director | Ingrid Joerg |
|---|---|
| EVP & Chief Financial Officer | Jack Guo |
| President of Aerospace & Transportation Business Unit | Philippe Hoffmann |
| Senior VP of Manufacturing Excellence & CTO | Ludovic Piquier |
| Director of Investor Relations | Jason Hershiser |
Major Backers & Investors (CSTM)
Notable institutional backers of Constellium SE include Bpifrance SA, Morgan Stanley, American Century Companies Inc, according to Nexqual as of October 29, 2026 at 06:47 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bpifrance SA | 6.2% |
| Morgan Stanley | 4.56% |
| American Century Companies Inc | 3.11% |
| T. Rowe Price | 2.2% |
| Arrowstreet Capital, Limited Partnership | 2.1% |
| Kinetic Partners Management, LP | 1.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.45% |
| Vanguard Group | 3.24% |
| State Street | 2.18% |
| Nuveen | 2.04% |
Source: Nexqual, October 29, 2026 at 06:47 UTC.
From Constellium SE's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- We believe that we are one of the largest providers of aluminum automotive crash management systems globally, and our customers include some of the largest North American and European car manufacturers.
- By leveraging our unique R&D partnership with the Brunel University in the United Kingdom, we have developed proprietary alloys and manufacturing technology which have enabled us to deliver high-quality and cost-effective products to our automotive customers.
- We invested $51 million, $49 million and $52 million in R&D in the years ended December 31, 2025, 2024 and 2023, respectively.
- To achieve these objectives, we have built a business strategy centered around six core principles: We are primarily focused on our strategic end-markets including aerospace, packaging and automotive, in which we have leading positions and long-standing relationships with many of the key manufacturers.
Partnerships
- We work in close collaboration with our customers to develop highly engineered solutions to fulfill their specific requirements.
- In each of our end-markets, we closely collaborate with our customers to complete a rigorous product qualification process, which requires substantial time and investment and creates high switching costs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CENX | Century Aluminum Company | USD 35.1 | ▲ 5.22% |
| KALU | Kaiser Aluminum Corporation | USD 120.85 | ▲ 3.96% |
| AA | Alcoa Corporation | USD 40.21 | ▲ 0.7% |
| GFI | Gold Fields Limited | USD 36.23 | ▲ 1.4% |
| NTR | Nutrien Ltd. | USD 69.07 | ▼ 0.43% |
| VMC | Vulcan Materials Company (Holdi | USD 265 | ▲ 0.95% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 06:47 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt